Welcome to our dedicated page for Connect Biopharma Holdings SEC filings (Ticker: CNTB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Connect Biopharma Holdings Limited filings document regulatory disclosures for a Cayman Islands clinical-stage biopharmaceutical issuer developing rademikibart for inflammatory diseases. Recent Form 8-K reports cover operating and financial results, clinical and regulatory updates tied to rademikibart, and Regulation FD disclosures.
The filing record also includes governance and capital-structure matters, including board composition, insider purchase disclosures, material agreements, ADR-program and deposit-agreement disclosures, and the relationship between American depositary shares and ordinary shares. These filings frame the company’s emerging-growth-company status, public-company reporting obligations and risk-related clinical development disclosures.
Connect Biopharma Holdings has received a Notice of Effectiveness from the SEC for their Form F-3 registration statement (File No. 333-287918), which became effective on June 26, 2025 at 4:00 P.M.
Form F-3 is a securities registration statement used by foreign companies to register various types of securities offerings in the United States. The effectiveness of this filing indicates that Connect Biopharma can now proceed with their planned securities offering as outlined in the registration statement.
This development is significant for investors as it enables the company to access U.S. capital markets and potentially raise additional funds through various securities offerings, including debt or equity securities, depending on the specifics outlined in the F-3 registration statement.